Aducanumab (Aduhelm) at the University of Florida
On June 7, 2021, the FDA approved the medication Aducanumab (Aduhelm) for use in Alzheimer’s disease. Amyloid beta may be an important protein in the progression of Alzheimer’s disease. Aduhelm is an antibody (i.e., a protein that helps your immune system to remove amyloid beta protein from your brain).
Currently, the manufacturer plans to make the medication available later this year. Insurance companies and Medicare have not yet made coverage decisions.
As many have heard in the media, the FDA approval was controversial. Professional organizations are currently developing guidance for providers.
The University of Florida Memory Disorders Center is awaiting information regarding insurance and Medicare coverage and further guidance from professional organizations to inform our approach to the medication when it becomes available. We apologize that there is not enough information at this time to make any plans for treatment.